2 ms·
> This is incorrect. There are ongoing phase 3 clinical trials for nasally applied esketamine that will lead to FDA approval if succesfully reviewed. Specifica
by shawnz 9y ago
> This is incorrect. There are ongoing phase 3 clinical trials for nasally applied esketamine that will lead to FDA approval if succesfully reviewed.
Specifically esketamine, not ketamine, because focusing on this specific isomer was the only way to get a new patent.
What if racemic ketamine performs better than esketamine? We'll never know because they won't test that.
- jeffreyrogers 9y agoDo you have a source for that? You can get a patent on a new use for something that already exists if the new use is a non-obvious advance over the prior art.
- TTPrograms 9y agoRacemic ketamine is also dirt cheap, while esketamine might be absurdly expensive after being patented.
- tibuma 9y ago> What if racemic ketamine performs better than esketamine? We'll never know because they won't test that. It's quite likely some public institutions (e.g., universities, public research labs, etc.) or other countries (e.g., in India, China) will test exactly that. It's also in their interest to pubblish the results. So we'll get to know the differences between racemic ketamine, esketamine and arketamine. The question is if different variants will also be approved, which is much more expensive.